《大行》招銀國際升三生製藥(01530.HK)目標價至9.91元 PD-1/VEGF展現優效潛力

阿斯達克財經

01-27

招銀國際發表報告指，三生製藥(01530.HK) 707(PD-1/VEGF)近期公佈707(PD-1/VEGF)的II期臨牀早期數據，展現優效潛力。在單藥一線治療PD-L1+、EGFR/ALK WT NSCLC的試驗中，10mg/kg Q3W劑量組有24例患者經歷了至少2次腫瘤評估，ORR達到70.8%，高於依沃西單抗(康方生物AK112)在Ib期(HARMONi-5，Link)和III期(HARMONi-2，Link)臨牀試驗中的60%和50%ORR。該行將持續關注後續PFS等數據讀出。公司計劃在今年啓動707治療NSCLC和CRC的III期臨牀試驗。

招銀國際維持對三生製藥“買入”評級，目標價由9.81元升至9.91元，指公司估值吸引、盈利增長穩健、創新管線具備出海潛力，預期公司2025年收入和淨利潤將分別按年增長12%和13%。(ha/k)(港股報價延遲最少十五分鐘。沽空資料截至 2025-01-24 16:25。)

AASTOCKS新聞

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2506313296"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506313296\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2506313296?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg","is_english":false,"pubTime":"2025-01-27 09:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506313296","market":"other","top_or_hot":-1,"title":"《大行》招銀國際升三生製藥(01530.HK)目標價至9.91元  PD-1/VEGF展現優效潛力","media":"阿斯達克財經","content":"<html><body><div> <span> <p>招銀國際發表報告指，<a href=\"https://laohu8.com/S/01530\">三生製藥</a>(01530.HK)<span> </span>707(PD-1/VEGF)近期公佈707(PD-1/VEGF)的II期臨牀早期數據，展現優效潛力。在單藥一線治療PD-L1+、EGFR/ALK WT NSCLC的試驗中，10mg/kg Q3W劑量組有24例患者經歷了至少2次腫瘤評估，ORR達到70.8%，高於依沃西單抗(<a href=\"https://laohu8.com/S/09926\">康方生物</a>AK112)在Ib期(HARMONi-5，Link)和III期(HARMONi-2，Link)臨牀試驗中的60%和50%ORR。該行將持續關注後續PFS等數據讀出。公司計劃在今年啓動707治療NSCLC和CRC的III期臨牀試驗。<br/><span></span><br/>招銀國際維持對三生製藥“買入”評級，目標價由9.81元升至9.91元，指公司估值吸引、盈利增長穩健、創新管線具備出海潛力，預期公司2025年收入和淨利潤將分別按年增長12%和13%。(ha/k)(港股報價延遲最少十五分鐘。沽空資料截至 2025-01-24 16:25。)</p><div></div>AASTOCKS新聞 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行》招銀國際升三生製藥(01530.HK)目標價至9.91元  PD-1/VEGF展現優效潛力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行》招銀國際升三生製藥(01530.HK)目標價至9.91元  PD-1/VEGF展現優效潛力\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-01-27 09:18</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div> <span> <p>招銀國際發表報告指，<a href=\"https://laohu8.com/S/01530\">三生製藥</a>(01530.HK)<span> </span>707(PD-1/VEGF)近期公佈707(PD-1/VEGF)的II期臨牀早期數據，展現優效潛力。在單藥一線治療PD-L1+、EGFR/ALK WT NSCLC的試驗中，10mg/kg Q3W劑量組有24例患者經歷了至少2次腫瘤評估，ORR達到70.8%，高於依沃西單抗(<a href=\"https://laohu8.com/S/09926\">康方生物</a>AK112)在Ib期(HARMONi-5，Link)和III期(HARMONi-2，Link)臨牀試驗中的60%和50%ORR。該行將持續關注後續PFS等數據讀出。公司計劃在今年啓動707治療NSCLC和CRC的III期臨牀試驗。<br/><span></span><br/>招銀國際維持對三生製藥“買入”評級，目標價由9.81元升至9.91元，指公司估值吸引、盈利增長穩健、創新管線具備出海潛力，預期公司2025年收入和淨利潤將分別按年增長12%和13%。(ha/k)(港股報價延遲最少十五分鐘。沽空資料截至 2025-01-24 16:25。)</p><div></div>AASTOCKS新聞 </span> </div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1413477/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生製藥","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1413477/latest-news/AAFN","article_id":"2506313296","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131519775_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506313296","pubTimestamp":1737940680,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"招銀國際發表報告指，三生製藥707近期公佈707的II期臨牀早期數據，展現優效潛力。該行將持續關注後續PFS等數據讀出。公司計劃在今年啓動707治療NSCLC和CRC的III期臨牀試驗。招銀國際維持對三生製藥“買入”評級，目標價由9.81元升至9.91元，指公司估值吸引、盈利增長穩健、創新管線具備出海潛力，預期公司2025年收入和淨利潤將分別按年增長12%和13%。(港股報價延遲最少十五分鐘。沽空資料截至 2025-01-24 16:25。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01530":"三生制药"},"translate_title":"\"Big Bank\" CMB International upgrades 3SBio (01530. HK) target price to 9.91 yuan PD-1/VEGF shows superior potential","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"招銀國際發表報告指，三生製藥(01530.HK) 707(PD-1/VEGF)近期公佈707(PD-1/VEGF)的II期臨牀早期數據，展現優效潛力。在單藥一線治療PD-L1+、EGFR/ALK WT NSCLC的試驗中，10mg/kg Q3W劑量組有24例患者經歷了至少2次腫瘤評估，ORR達到70.8%，高於依沃西單抗(康方生物AK112)在Ib期(HARMONi-5，Link)和III期(HARMONi-2，Link)臨牀試驗中的60%和50%ORR。該行將持續關注後續PFS等數據讀出。公司計劃在今年啓動707治療NSCLC和CRC的III期臨牀試驗。招銀國際維持對三生製藥“買入”評級，目標價由9.81元升至9.91元，指公司估值吸引、盈利增長穩健、創新管線具備出海潛力，預期公司2025年收入和淨利潤將分別按年增長12%和13%。(ha/k)(港股報價延遲最少十五分鐘。沽空資料截至 2025-01-24 16:25。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}